WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 300165
CAS#: 62357-86-2 (acetate trihydrate)
Description: Desmopressin acetate is a synthetic replacement for vasopressin, the hormone that reduces urine production. It may be taken nasally, intravenously, or as a tablet. Doctors prescribe Desmopressin most frequently for treatment of diabetes insipidus or nocturnal enuresis. Desmopressin (1-desamino-8-D-arginine vasopressin) is a modified form of the normal human hormone arginine vasopressin, a peptide containing nine amino acids. Medical use of Desmopressin acetate includes: (a) bed wetting; (b) nighttime urination; (c) clotting disorders; (d) diabetes insipidus.
MedKoo Cat#: 300165
Name: Desmopressin acetate trihydrate
CAS#: 62357-86-2 (acetate trihydrate)
Chemical Formula: C48H74N14O17S2
Exact Mass:
Molecular Weight: 1189.32
Elemental Analysis: C, 48.72; H, 6.30; N, 16.57; O, 22.99; S, 5.42
Desmopressin Acetate trihydrate, CAS#62357-86-2, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Related CAS #: 62357-86-2 (acetate trihydrate) 69-25-0 (free base) 62288-83-9 (acetate)
Synonym: Adiuretin; Deamino Arginine Vasopressin; Desmogalen; Vasopressin 1-Desamino-8-arginine; trade names: DDAVP, DesmoMelt, Minirin, Minirin Melt, Octim, Stimate; Nocutil. Pubchem ID64759
IUPAC/Chemical Name: (S)-1-((4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)-N-((R)-1-((2-amino-2-oxoethyl)amino)-5-guanidino-1-oxopentan-2-yl)pyrrolidine-2-carboxamide acetate trihydrate
InChi Key: YNKFCNRZZPFMEX-XHPDKPNGSA-N
InChi Code: InChI=1S/C46H64N14O12S2.C2H4O2.3H2O/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25;1-2(3)4;;;/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52);1H3,(H,3,4);3*1H2/t28-,29+,30+,31+,32+,33+,34+;;;;/m1..../s1
SMILES Code: O=C([C@H]1N(C([C@@H](NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC2=CC=CC=C2)NC([C@H](CC3=CC=C(O)C=C3)N4)=O)=O)=O)=O)CSSCCC4=O)=O)CCC1)N[C@H](CCCNC(N)=N)C(NCC(N)=O)=O.CC(O)=O.[H]O[H].[H]O[H].[H]O[H]
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Soluble in in water | 100.0 |
The following data is based on the product molecular weight 1189.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Friedman FM, Weiss JP. Desmopressin in the treatment of nocturia: clinical evidence and experience. Ther Adv Urol. 2013 Dec;5(6):310-7. doi: 10.1177/1756287213502116. Review. PubMed PMID: 24294289; PubMed Central PMCID: PMC3825109.
2: Karanth L, Barua A, Kanagasabai S, Nair NS. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database Syst Rev. 2013 Apr 30;4:CD009824. doi: 10.1002/14651858.CD009824.pub2. Review. PubMed PMID: 23633378.
3: Pape E, Béné J, Buchdahl AL, Gautier S, Hatron PY, Lambert M. Desmopressin-related myocardial infarction in a patient with Wegener's granulomatosis: a case report and review of the literature. J Mal Vasc. 2013 Feb;38(1):43-6. doi: 10.1016/j.jmv.2012.11.001. Epub 2012 Dec 21. Review. PubMed PMID: 23265678.
4: Deshpande AV, Caldwell PH, Sureshkumar P. Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics). Cochrane Database Syst Rev. 2012 Dec 12;12:CD002238. doi: 10.1002/14651858.CD002238.pub2. Review. PubMed PMID: 23235587.
5: Juul KV, Klein BM, Nørgaard JP. Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn. 2013 Apr;32(4):363-70. doi: 10.1002/nau.22306. Epub 2012 Sep 12. Review. PubMed PMID: 22972524.
6: Verrua E, Mantovani G, Ferrante E, Noto A, Sala E, Malchiodi E, Iapichino G, Peccoz PB, Spada A. Severe water intoxication secondary to the concomitant intake of non-steroidal anti-inflammatory drugs and desmopressin: a case report and review of the literature. Hormones (Athens). 2013 Jan-Mar;12(1):135-41. Review. PubMed PMID: 23624139.
7: Zong H, Yang C, Peng X, Zhang Y. Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials. Int Urol Nephrol. 2012 Apr;44(2):377-84. doi: 10.1007/s11255-011-0054-3. Epub 2011 Sep 7. Review. PubMed PMID: 21898039.
8: Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus. 2011 Oct;9(4):377-82. doi: 10.2450/2011.0113-10. Epub 2011 Jul 18. Review. PubMed PMID: 21839010; PubMed Central PMCID: PMC3200405.
9: Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 2012 Jan;18(1):25-33. doi: 10.1111/j.1365-2516.2011.02573.x. Epub 2011 May 30. Review. PubMed PMID: 21624012.
10: Alonso DF, Ripoll GV, Garona J, Iannucci NB, Gomez DE. Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol. 2011 Nov;12(11):1974-80. Review. PubMed PMID: 21470136; PubMed Central PMCID: PMC3257748.
Related CAS#
62357-86-2 (Desmopressin acetate trihydrate);
62288-83-9 (Desmopressin acetate);
16679-58-6 (Desmopressin free base);
16789-98-3 (Desmopressin diacetate).
Note: The drug API approved by FDA is Desmopressin acetate trihydrate, which CAS# is 62357-86-2 with Chemical Formula: C48H74N14O17S2 and Molecular Weight: 1183.31.
Other forms of Desmopressin:
Desmopressin (not FDA approved drug API)
CAS# 16679-58-6 (desmopressin); Chemical Formula: C47H64N12O13S2
Exact Mass: 1068.41572; Molecular Weight: 1069.21
Elemental Analysis: C, 52.80; H, 6.03; N, 15.72; O, 19.45; S, 6.00
Desmopressin Acetate (not FDA approved drug API)
CAS#62288-83-9 (desmopressin acetate); Chemical Formula: C49H68N12O15S2
Molecular Weight: 1129.26
Elemental Analysis: C, 52.12; H, 6.07; N, 14.88; O, 21.25; S, 5.68
Desmopressin diacetate (not FDA approved drug API)
CAS#16789-98-3 (desmopressin diacetate)
Chemical Formula: C50H72N14O16S2; Molecular Weight: 1189.32
Elemental Analysis: C, 50.49; H, 6.10; N, 16.49; O, 21.52; S, 5.39
Mode of action: Desmopressin works by limiting the amount of water that is eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of factor VIII from endothelial cells due to stimulation of the V1a receptor. Desmopressin is degraded more slowly than recombinant vasopressin, and requires less frequent administration. In addition, it has little effect on blood pressure, while vasopressin may cause arterial hypertension. [source: http://en.wikipedia.org/wiki/Desmopressin].
INDICATIONS: Central Diabetes Insipidus: DDAVP Tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to DDAVP can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis: DDAVP Tablets are indicated for the management of primary nocturnal enuresis. DDAVP may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. [source: http://www.rxlist.com/ddavp-drug.htm].
